Inscripción
profesionales sanitarios
para pacientes y familiares
Days after #ESMO26
FAN-TAS-TIC good news
@Genmab $GMAB has announced that Petosentamab, a bispecific anti EGFRxLGR5 plus pembro meets both primary endpoints possibly becoming the new 1st line in R/M PDL1+ HNSCC
✅ OS . OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001
✅ ORR. 3.17
Today, we announced positive Phase 3 topline results for our investigational therapy in head and neck cancer. The findings reinforce the potential of our differentiated antibody science and reflect our continued commitment to developing transformative medicines for people living
#HNSCC #ESMO26
RADIAN-TTCC Dostarlimab and niraparib in the CRT soace in LA PD-L1+ disease
An stunning effort from Dr Oliva, rest investigators and the spanish cooperative group @ttccgroup
@myESMO @OncoAlert @brunolarvol
@FundacionTTCC
Days after #ESMO26
FAN-TAS-TIC good news
@Genmab $GMAB has announced that Petosentamab, a bispecific anti EGFRxLGR5 plus pembro meets both primary endpoints possibly becoming the new 1st line in R/M PDL1+ HNSCC
✅ OS . OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001
✅ ORR. 3.17
Today, we announced positive Phase 3 topline results for our investigational therapy in head and neck cancer. The findings reinforce the potential of our differentiated antibody science and reflect our continued commitment to developing transformative medicines for people living
#HNSCC #ESMO26
RADIAN-TTCC Dostarlimab and niraparib in the CRT soace in LA PD-L1+ disease
An stunning effort from Dr Oliva, rest investigators and the spanish cooperative group @ttccgroup
@myESMO @OncoAlert @brunolarvol
@FundacionTTCC
Days after #ESMO26
FAN-TAS-TIC good news
@Genmab $GMAB has announced that Petosentamab, a bispecific anti EGFRxLGR5 plus pembro meets both primary endpoints possibly becoming the new 1st line in R/M PDL1+ HNSCC
✅ OS . OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001
✅ ORR. 3.17
Today, we announced positive Phase 3 topline results for our investigational therapy in head and neck cancer. The findings reinforce the potential of our differentiated antibody science and reflect our continued commitment to developing transformative medicines for people living
#HNSCC #ESMO26
RADIAN-TTCC Dostarlimab and niraparib in the CRT soace in LA PD-L1+ disease
An stunning effort from Dr Oliva, rest investigators and the spanish cooperative group @ttccgroup
@myESMO @OncoAlert @brunolarvol
@FundacionTTCC
TTCC en cifras
